Sun Biopharma Appoints CFO
This article was originally published in Scrip
Sun BioPharma, Inc., a company focused on pancreatic diseases, has appointed Scott Kellen vice-president of finance and chief financial officer (CFO) effective immediately. Kellen brings over 20 years of healthcare, corporate finance and capital markets experience to Sun Biopharma and joins the company from Kips Bay Medical, Inc., a medical device company, where he was chief operating officer and CFO. Previously, Kellen was director of finance at Transoma Medical, Inc., and corporate controller for ev3, Inc. during its IPO and follow-on offerings.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.